DiaMedica Therapeutics Inc.
MINNEAPOLIS, MN · CIK 0001401040 · Biotech
synthetic proteins for therapeutic treatment
diamedica.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $110M
- 6 Form D · Jul 2025
- 15 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 0 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $200,870 | |
| Private capital raised | Form D · SEC | $29,999,995 | |
| Private capital raised | Form D · SEC | $750,000 | |
| Private capital raised | Form D · SEC | $37,536,853 | |
| Private capital raised | Form D · SEC | $11,800,000 | |
| Private capital raised | Form D · SEC | $30,100,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1109 | Proximity Biosciences LLC | — | — |
| 1110 | EMMUNE INC | — | — |
| 1111 | EPPIN PHARMA, INC. | — | — |
| 1112 | DiaMedica Therapeutics Inc. | — | $110M |
| 1113 | JUN INNOVATIONS INC | — | — |
| 1114 | COMPANION SCIENCES, INC. | — | — |
| 1115 | Mu Therapeutics Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Harry Alcorn Jr.Executive Officer
- Amy BurroughsDirector
- Dominic CundariExecutive Officer
- Julie DavesExecutive Officer
- Sydney GilmanExecutive Officer
- Michael GiuffreDirector
- R. GiuffreDirector
- Kirsten GruisExecutive Officer
- David GurveyExecutive Officer
- Scott KellenExecutive Officer
- Richard KuntzDirector
- Tanya LewisDirector
- Lorianne MasuokaExecutive Officer
- Daniel O'ConnorDirector
- Paul PapiExecutive Officer
- James ParsonsDirector
- Rick PaulsDirector · Executive Officer
- Richard PilnikDirector
- Charles SembaDirector
- Todd VerdoornExecutive Officer
- David WambekeExecutive Officer
- Zhenyu XiaoDirector
Patents
- Dosage Forms Of Tissue Kallikrein 1application
- Intravenous Compositions Of Tissue KALLIKREIN-1 And Related Methodsapplication
- Tissue KALLIKREIN-1 For Treating Pregnancy Disordersapplication
- Tissue KALLIKREIN-1 For Treating Chronic Kidney Diseaseapplication
- Tissue KALLIKREIN-1 For Treating Pregnancy Disordersapplication
- Intravenous Compositions Of Tissue KALLIKREIN-1 And Related Methodsapplication
- Tissue KALLIKREIN-1 For Treating Pregnancy Disordersapplication
- Intravenous Compositions Of Tissue KALLIKREIN-1 And Related Methodsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.